Navigation Links
Clinipace Recently Awarded $2.8 Million to Manage Three New Clinical Projects
Date:2/26/2009

Projects include electronic data capture (EDC), data management services, clinical monitoring, and biostatistics for several early-stage clinical trials and registries

Morrisville, N.C. (PRWEB) February 26, 2009 -- Clinipace, a growing clinical research solutions company, today announced that it has been awarded three new projects in 2009 worth, in aggregate, more than $2.8 million.

With a focus on emerging and mid-tier life science firms who are looking for a better way to manage their clinical trials, Clinipace is able to fill operational gaps while boosting sponsor visibility and project efficiencies through its web-based TEMPO™ research platform.

"These new clients appreciate that we're a technology-centric service company, and that we think differently than traditional service providers," said Jeff Williams, Chief Executive Officer at Clinipace. "During the evaluation process, our team worked really hard to understand our prospective clients' challenges, and we're excited that our particular formula of technology and research services was a compelling value for them."

Clinipace recently launched a "Right-Sized" approach to managing clinical trials and registries, which optimizes trial resources through the right mix of technology and services. Smaller life science firms are becoming increasingly wary of receiving over-priced, over-stuffed project budgets typically found in the bids of traditional service providers, and Clinipace's unique model, along with its fixed-price guarantee, were key factors in being selected to help these clients.

"Committed to full transparency, efficiency and lower cost, all of our services are built upon our TEMPO™ web-based platform," explains Williams. "With our technology-based service model we're able to save companies 30-50% vs. what a traditional CRO would charge without compromising quality or service-levels. In today's environment that is not only important, it's absolutely vital to our clients," continues Williams.

About Clinipace
Clinipace is an experienced clinical research solutions company providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% - 50% savings compared to similar service providers. Learn more at clinipace.com.

# # #

Read the full story at http://www.prweb.com/releases/2009/02/prweb2188154.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Two Pharmaceutical Firms Select Clinipace to Deploy New Grant Management Solution
2. On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace
3. Recently Reported Childhood Deaths from Influenza Are a Stark Reminder to Vaccinate Now
4. FamilyLife Offers Economic Relief and Hope for Baltimore Marriages by Inviting Recently Unemployed Couples to Attend Marriage Conference for Free
5. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
6. 1.2 Million Dollars Recently Awarded to Institute for Myeloma and Bone Cancer Research
7. Benefits of a Lifeclinic LC300 Automated Blood Pressure Monitor Recently Featured on Daytime Medical Talk Show
8. HealthInsuranceFinders.com Publishes Health Insurance Guide for the Recently Unemployed
9. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
10. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
11. CoolTouch Introduces CoolLipo(TM) Laser System, Recently FDA Cleared for Laser-Assisted Lipolysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... Current Meditation , a new meditation ... the U.S. starting this spring. Current Meditation focuses on “meditation for the modern ... Meditation will be the first meditation concept in the U.S. offering franchising opportunities, ...
(Date:2/23/2017)... ... February 23, 2017 , ... The ... the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to ... autism spectrum disorder (ASD) to see films in an environment that accommodates their ...
(Date:2/23/2017)... ... 23, 2017 , ... CALNOC, the nation’s first and only nursing quality indicators ... – Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. , ... Health System in Seattle since 2000. In addition to his role at Virginia Mason, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm Study, ... children aged 3-8 with Autism, is now enrolling at three new sites. These new ... United States. , “There are currently no approved drugs that address the core ...
(Date:2/23/2017)... ... 2017 , ... Thomas Vas-Don suffered from severe injury due to ... able to successfully recover. In “ Origin & Insertion Charts for Massage Therapists ” ... principals of massage, anatomy , trigger points and referral pain patterns . ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 On Wednesday, ... day as four out of nine sectors finished the trading ... managed a flat closing. Major US indices were also mixed ... the day at 5,860.63, slightly down by 0.09%; the Dow ... and the S&P 500 closed at 2,362.82, down 0.11%. This ...
(Date:2/23/2017)... , February 23, 2017 ML Capital ... in Colorado Highlife Tours , a ... plan in partnership with Puration, Inc. (USOTC: PURA) to enter ... cannabis tours product. The Colorado Highlife Tours acquisition announced today is ... tourism strategy. ...
(Date:2/23/2017)... VANCOUVER, British Columbia , Feb. 23, 2017 ... today announced its year end 2016 financial results.  ... 2017, OncoGenex, and Achieve Life Science, Inc., a privately held ... a definitive merger agreement under which OncoGenex will acquire ... proposed merger, Achieve,s stockholders are expected to own 75% ...
Breaking Medicine Technology: